id,InchiKey,Mol_name (IUPAC),IUPAC,Smiles,Pubchem_ID,CHEMBL_ID,Database,Assay,Phenotypic Assay ,Observation,Target,Receptor source/Animal Model,IC50,EC50,PEC50,DOI,Activity,canonical_smiles,inchikey
SD_044,FNSGSFGLTWLQNZ-UHFFFAOYSA-N,1e,"2-(4-((6-(7-methyl-2,3-dihydrobenzo[d]oxazol-2-yl)-2-propyl-1H-indol-1-yl)methyl)indolin-1-yl)benzoic acid",O=C(O)C1=CC=CC=C1N2C3=C(CC2)C(CN4C5=C(C=C4CCC)C=CC(C6OC7=C(N6)C=CC=C7C)=C5)=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.0053 ± 0.0011,,,10.1021/acsmedchemlett.8b00335,Active,CCCc1cc2ccc(C3Nc4cccc(C)c4O3)cc2n1Cc1cccc2c1CCN2c1ccccc1C(=O)O,FNSGSFGLTWLQNZ-UHFFFAOYSA-N
SD_045,MTZXOTRUDRHIGY-UHFFFAOYSA-N,1f,"2-(4-((2-butyl-6-(7-methyl-2,3-dihydrobenzo[d]oxazol-2-yl)-1H-indol-1-yl)methyl)indolin-1-yl)benzoic acid",O=C(O)C1=CC=CC=C1N2C3=C(CC2)C(CN4C5=C(C=C4CCCC)C=CC(C6OC7=C(N6)C=CC=C7C)=C5)=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.0105 ± 0.0018,,,10.1021/acsmedchemlett.8b00335,Active,CCCCc1cc2ccc(C3Nc4cccc(C)c4O3)cc2n1Cc1cccc2c1CCN2c1ccccc1C(=O)O,MTZXOTRUDRHIGY-UHFFFAOYSA-N
SD_050,FNSGSFGLTWLQNZ-UHFFFAOYSA-N,2e,"2-(4-((6-(7-methyl-2,3-dihydrobenzo[d]oxazol-2-yl)-2-propyl-1H-indol-1-yl)methyl)indolin-1-yl)benzoic acid",O=C(O)C1=CC=CC=C1N2C3=C(CC2)C(CN4C5=C(C=C4CCC)C=CC(C6OC7=C(N6)C=CC=C7C)=C5)=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.0056 ± 0.0008,,,10.1021/acsmedchemlett.8b00335,Active,CCCc1cc2ccc(C3Nc4cccc(C)c4O3)cc2n1Cc1cccc2c1CCN2c1ccccc1C(=O)O,FNSGSFGLTWLQNZ-UHFFFAOYSA-N
SD_051,MTZXOTRUDRHIGY-UHFFFAOYSA-N,2f,"2-(4-((2-butyl-6-(7-methyl-2,3-dihydrobenzo[d]oxazol-2-yl)-1H-indol-1-yl)methyl)indolin-1-yl)benzoic acid",O=C(O)C1=CC=CC=C1N2C3=C(CC2)C(CN4C5=C(C=C4CCCC)C=CC(C6OC7=C(N6)C=CC=C7C)=C5)=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.0097 ± 0.0009,,,10.1021/acsmedchemlett.8b00335,Active,CCCCc1cc2ccc(C3Nc4cccc(C)c4O3)cc2n1Cc1cccc2c1CCN2c1ccccc1C(=O)O,MTZXOTRUDRHIGY-UHFFFAOYSA-N
SD_052,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,Losartan,"(1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol",OCC1=C(N=C(N1CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2)CCCC)Cl,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.0146 ± 0.0016,,,10.1021/acsmedchemlett.8b00335,Active,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,PSIFNNKUMBGKDQ-UHFFFAOYSA-N
SD_068,FAKRSMQSSFJEIM-RQJHMYQMSA-N,Captopril,((S)-3-mercapto-2-methylpropanoyl)-L-proline,C[C@@H](C(N1CCC[C@H]1C(O)=O)=O)CS,44093.0,,ChEMBL,In vitro calcium channel blocking assays,,,ACE,,,,,10.1016/j.bmc.2009.03.008,Active,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,FAKRSMQSSFJEIM-RQJHMYQMSA-N
SD_081,LSNPOGOZVAHETR-UHFFFAOYSA-N,13,2-methoxy-4-(5-nitro-1H-benzo[d]imidazol-2-yl)phenol,COC1=C(O)C=CC(C2=NC3=CC([N+]([O-])=O)=CC=C3N2)=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,Vascular smooth muscle,rat aorta rings pre-contracted with noradrenaline and spontaneously hypertensive rats,,19.49 ± 1.79,,10.1016/j.bmc.2010.04.027,Active,COc1cc(-c2nc3cc([N+](=O)[O-])ccc3[nH]2)ccc1O,LSNPOGOZVAHETR-UHFFFAOYSA-N
SD_091,SIVGPWBPJHPSCL-FQEVSTJZSA-N,2,"(S)-2-(N-((5'-fluoro-2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)butyramido)pentanoic acid",O=C(CCC)N([C@@H](CCC)C(O)=O)CC1=CC=C(C2=C(C3=NOC(N3)=O)C=CC(F)=C2)C=C1,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,Spontaneously hypertensive rats,20.81 ± 0.12,,,10.1016/j.bmc.2012.02.003,Active,CCCC(=O)N(Cc1ccc(-c2cc(F)ccc2-c2noc(=O)[nH]2)cc1)[C@@H](CCC)C(=O)O,SIVGPWBPJHPSCL-FQEVSTJZSA-N
SD_092,ACWBQPMHZXGDFX-QFIPXVFZSA-N,Valsartan,"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine",CC([C@H](N(CC1=CC=C(C2=C(C3=NN=NN3)C=CC=C2)C=C1)C(CCCC)=O)C(O)=O)C,60846.0,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,Spontaneously hypertensive rats,2.64 ± 0.70,,,10.1016/j.bmc.2012.02.003,Active,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,ACWBQPMHZXGDFX-QFIPXVFZSA-N
SD_093,YOSHYTLCDANDAN-UHFFFAOYSA-N,Irbesartan,"3-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one",O=C(CCC)N([C@@H](CCC)C(O)=O)CC1=CC=C(C2=C(C3=NOC(N3)=O)C=CC(F)=C2)C=C1,3749.0,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,Spontaneously hypertensive rats,0.58 ± 0.22,,,10.1016/j.bmc.2012.02.003,Active,CCCC(=O)N(Cc1ccc(-c2cc(F)ccc2-c2noc(=O)[nH]2)cc1)[C@@H](CCC)C(=O)O,SIVGPWBPJHPSCL-FQEVSTJZSA-N
SD_094,RLAWWYSOJDYHDC-BZSNNMDCSA-N,Lisinopril,((S)-1-carboxy-3-phenylpropyl)-L-lysyl-L-proline,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(O)=O)CCCCN)=O)O,5362119.0,,ChEMBL,In vitro calcium channel blocking assays,No,,HEK 293a,Human,443,,,10.1016/j.bmc.2013.05.031,Active,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,RLAWWYSOJDYHDC-BZSNNMDCSA-N
SD_095,HDACQVRGBOVJII-JBDAPHQKSA-N,Ramipril,"(2S,3aS,6aS)-1-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid",O=C(O)[C@@H]1C[C@]2([H])CCC[C@@]2(N1C([C@@H](N[C@@H](CCC3=CC=CC=C3)C(OCC)=O)C)=O)[H],5362129.0,,ChEMBL,In vitro calcium channel blocking assays,No,,HEK 293a,Human,414,,,10.1016/j.bmc.2013.05.031,Active,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,HDACQVRGBOVJII-JBDAPHQKSA-N
SD_096,XPCFTKFZXHTYIP-PMACEKPBSA-N,Benazepril,"2-((S)-3-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",O=C(CN1C([C@H](CCC2=C1C=CC=C2)N[C@@H](CCC3=CC=CC=C3)C(OCC)=O)=O)O,5362124.0,,ChEMBL,In vitro calcium channel blocking assays,No,,HEK 293a,Human,301,,,10.1016/j.bmc.2013.05.031,Active,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,XPCFTKFZXHTYIP-PMACEKPBSA-N
SD_097,TVLDNLINZRNKES-PBHICJAKSA-N,5f,"(2R,11aS)-10-(3-Bromobenzyl)-2-hydroxy-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione",O=C(N1[C@@]2([H])C[C@@H](O)C1)C3=CC=CC=C3N(CC4=CC=CC(Br)=C4)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,HEK 293a,Human,398,,,10.1016/j.bmc.2013.05.031,Active,O=C1[C@@H]2C[C@@H](O)CN2C(=O)c2ccccc2N1Cc1cccc(Br)c1,TVLDNLINZRNKES-PBHICJAKSA-N
SD_098,UTFPDQLPXOXPSM-PBHICJAKSA-N,5g,"(2R,11aS)-10-(4-Bromobenzyl)-2-hydroxy-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione",O=C(N1[C@@]2([H])C[C@@H](O)C1)C3=CC=CC=C3N(CC4=CC=C(Br)C=C4)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,HEK 293a,Human,496,,,10.1016/j.bmc.2013.05.031,Active,O=C1[C@@H]2C[C@@H](O)CN2C(=O)c2ccccc2N1Cc1ccc(Br)cc1,UTFPDQLPXOXPSM-PBHICJAKSA-N
SD_099,KWJXQSQVOWQQJY-PBHICJAKSA-N,5r,"(2R,11aS)-2-Hydroxy-10-(3,4,5-trimethoxybenzyl)-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione",O=C(N1[C@@]2([H])C[C@@H](O)C1)C3=CC=CC=C3N(CC4=CC(OC)=C(OC)C(OC)=C4)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,HEK 293a,Human,331,,,10.1016/j.bmc.2013.05.031,Active,COc1cc(CN2C(=O)[C@@H]3C[C@@H](O)CN3C(=O)c3ccccc32)cc(OC)c1OC,KWJXQSQVOWQQJY-PBHICJAKSA-N
SD_100,BEGAJSOBXUVZKP-ABAIWWIYSA-N,5v,"(2R,11aS)-10-((4-Bromothiophen-2-yl)methyl)-2-hydroxy-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione",O=C(N1[C@@]2([H])C[C@@H](O)C1)C3=CC=CC=C3N(CC4=CC(Br)=CS4)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,HEK 293a,Human,281,,,10.1016/j.bmc.2013.05.031,Active,O=C1[C@@H]2C[C@@H](O)CN2C(=O)c2ccccc2N1Cc1cc(Br)cs1,BEGAJSOBXUVZKP-ABAIWWIYSA-N
SD_101,RLAWWYSOJDYHDC-BZSNNMDCSA-N,Lisinopril,((S)-1-carboxy-3-phenylpropyl)-L-lysyl-L-proline,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(O)=O)CCCCN)=O)O,5362119.0,,ChEMBL,In vitro calcium channel blocking assays,No,,A549b,Human,307,,,10.1016/j.bmc.2013.05.031,Active,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,RLAWWYSOJDYHDC-BZSNNMDCSA-N
SD_102,HDACQVRGBOVJII-JBDAPHQKSA-N,Ramipril,"(2S,3aS,6aS)-1-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid",O=C(O)[C@@H]1C[C@]2([H])CCC[C@@]2(N1C([C@@H](N[C@@H](CCC3=CC=CC=C3)C(OCC)=O)C)=O)[H],5362129.0,,ChEMBL,In vitro calcium channel blocking assays,No,,A549b,Human,392,,,10.1016/j.bmc.2013.05.031,Active,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,HDACQVRGBOVJII-JBDAPHQKSA-N
SD_103,XPCFTKFZXHTYIP-PMACEKPBSA-N,Benazepril,"2-((S)-3-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",O=C(CN1C([C@H](CCC2=C1C=CC=C2)N[C@@H](CCC3=CC=CC=C3)C(OCC)=O)=O)O,5362124.0,,ChEMBL,In vitro calcium channel blocking assays,No,,A549b,Human,358,,,10.1016/j.bmc.2013.05.031,Active,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,XPCFTKFZXHTYIP-PMACEKPBSA-N
SD_104,TVLDNLINZRNKES-PBHICJAKSA-N,5f,"(2R,11aS)-10-(3-Bromobenzyl)-2-hydroxy-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione",O=C(N1[C@@]2([H])C[C@@H](O)C1)C3=CC=CC=C3N(CC4=CC=CC(Br)=C4)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,A549b,Human,400.4,,,10.1016/j.bmc.2013.05.031,Active,O=C1[C@@H]2C[C@@H](O)CN2C(=O)c2ccccc2N1Cc1cccc(Br)c1,TVLDNLINZRNKES-PBHICJAKSA-N
SD_105,UTFPDQLPXOXPSM-PBHICJAKSA-N,5g,"(2R,11aS)-10-(4-Bromobenzyl)-2-hydroxy-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione",O=C(N1[C@@]2([H])C[C@@H](O)C1)C3=CC=CC=C3N(CC4=CC=C(Br)C=C4)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,A549b,Human,486.7,,,10.1016/j.bmc.2013.05.031,Active,O=C1[C@@H]2C[C@@H](O)CN2C(=O)c2ccccc2N1Cc1ccc(Br)cc1,UTFPDQLPXOXPSM-PBHICJAKSA-N
SD_106,KWJXQSQVOWQQJY-PBHICJAKSA-N,5r,"(2R,11aS)-2-Hydroxy-10-(3,4,5-trimethoxybenzyl)-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione",O=C(N1[C@@]2([H])C[C@@H](O)C1)C3=CC=CC=C3N(CC4=CC(OC)=C(OC)C(OC)=C4)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,A549b,Human,418.7,,,10.1016/j.bmc.2013.05.031,Active,COc1cc(CN2C(=O)[C@@H]3C[C@@H](O)CN3C(=O)c3ccccc32)cc(OC)c1OC,KWJXQSQVOWQQJY-PBHICJAKSA-N
SD_107,BEGAJSOBXUVZKP-ABAIWWIYSA-N,5v,"(2R,11aS)-10-((4-Bromothiophen-2-yl)methyl)-2-hydroxy-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione",O=C(N1[C@@]2([H])C[C@@H](O)C1)C3=CC=CC=C3N(CC4=CC(Br)=CS4)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,A549b,Human,361,,,10.1016/j.bmc.2013.05.031,Active,O=C1[C@@H]2C[C@@H](O)CN2C(=O)c2ccccc2N1Cc1cc(Br)cs1,BEGAJSOBXUVZKP-ABAIWWIYSA-N
SD_114,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,Losartan,"(1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol",OCC1=C(N=C(N1CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2)CCCC)Cl,3961.0,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁,Spontaneously hypertensive rats,0.0035 ± 0.0003,,,10.1016/j.bmc.2014.02.008,Active,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,PSIFNNKUMBGKDQ-UHFFFAOYSA-N
SD_115,SONNWYBIRXJNDC-VIFPVBQESA-N,Phenylephrine,3-(1-hydroxy-2-(methylamino)ethyl)phenol,OC1=CC(C(CNC)O)=CC=C1,6041.0,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁A-adrenoceptor,Rats,,0.0550 ± 0.0094,,10.1016/j.bmc.2015.03.009,Active,CNCC(O)c1cccc(O)c1,SONNWYBIRXJNDC-UHFFFAOYSA-N
SD_116,VCKUSRYTPJJLNI-UHFFFAOYSA-N,Terazosin,"(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone",O=C(C1OCCC1)N2CCN(CC2)C3=NC(N)=C4C=C(C(OC)=CC4=N3)OC,5401.0,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁A-adrenoceptor,Rats,,0.0510 ± 0.0105,,10.1016/j.bmc.2015.03.009,Active,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC,VCKUSRYTPJJLNI-UHFFFAOYSA-N
SD_117,GWZKQAZNJFCKIR-UHFFFAOYSA-N,10e,1-{4-[4-(bis(4-Fluorophenyl)methyl)piperazin-1-yl]butyl}pyrrolidin-2-one hydrochloride,O=C1N(CCCCN2CCN(C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2)CCC1.[H]Cl,,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁A-adrenoceptor,Rats,,0.3291 ± 0.0413,,10.1016/j.bmc.2015.03.009,Active,Cl.O=C1CCCN1CCCCN1CCN(C(c2ccc(F)cc2)c2ccc(F)cc2)CC1,GWZKQAZNJFCKIR-UHFFFAOYSA-N
SD_118,RFFLBWRKQXJYFL-UHFFFAOYSA-N,10h,1-{4-[4-(2-Chlorophenyl)piperazin-1-yl]butyl}pyrrolidin-2-one hydrochloride,O=C1N(CCCCN2CCN(C3=CC=CC=C3Cl)CC2)CCC1.[H]Cl,,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁A-adrenoceptor,Rats,,0.1382 ± 0.0219,,10.1016/j.bmc.2015.03.009,Active,Cl.O=C1CCCN1CCCCN1CCN(c2ccccc2Cl)CC1,RFFLBWRKQXJYFL-UHFFFAOYSA-N
SD_119,SONNWYBIRXJNDC-VIFPVBQESA-N,Phenylephrine,3-(1-hydroxy-2-(methylamino)ethyl)phenol,OC1=CC(C(CNC)O)=CC=C1,6041.0,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁B-adrenoceptor,Rats,,0.006 ± 0.001,,10.1016/j.bmc.2015.03.009,Active,CNCC(O)c1cccc(O)c1,SONNWYBIRXJNDC-UHFFFAOYSA-N
SD_120,VCKUSRYTPJJLNI-UHFFFAOYSA-N,Terazosin,"(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone",O=C(C1OCCC1)N2CCN(CC2)C3=NC(N)=C4C=C(C(OC)=CC4=N3)OC,5401.0,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁B-adrenoceptor,Rats,,0.0005 ± 0.0001,,10.1016/j.bmc.2015.03.009,Active,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC,VCKUSRYTPJJLNI-UHFFFAOYSA-N
SD_122,GWZKQAZNJFCKIR-UHFFFAOYSA-N,10e,1-{4-[4-(bis(4-Fluorophenyl)methyl)piperazin-1-yl]butyl}pyrrolidin-2-one hydrochloride,O=C1N(CCCCN2CCN(C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2)CCC1.[H]Cl,,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁B-adrenoceptor,Rats,,0.1311 ± 0.0113,,10.1016/j.bmc.2015.03.009,Active,Cl.O=C1CCCN1CCCCN1CCN(C(c2ccc(F)cc2)c2ccc(F)cc2)CC1,GWZKQAZNJFCKIR-UHFFFAOYSA-N
SD_125,RFFLBWRKQXJYFL-UHFFFAOYSA-N,10h,1-{4-[4-(2-Chlorophenyl)piperazin-1-yl]butyl}pyrrolidin-2-one hydrochloride,O=C1N(CCCCN2CCN(C3=CC=CC=C3Cl)CC2)CCC1.[H]Cl,,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁B-adrenoceptor,Rats,,0.0025 ± 0.0005,,10.1016/j.bmc.2015.03.009,Active,Cl.O=C1CCCN1CCCCN1CCN(c2ccccc2Cl)CC1,RFFLBWRKQXJYFL-UHFFFAOYSA-N
SD_151,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,1,"(1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol",OCC1=C(N=C(N1CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2)CCCC)Cl,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.0347,,,https://doi.org/10.1021/jm00030a013,Active,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,PSIFNNKUMBGKDQ-UHFFFAOYSA-N
SD_169,LZFZMUMEGBBDTC-QEJZJMRPSA-N,enalaprilat,((S)-1-carboxy-3-phenylpropyl)-L-alanyl-L-proline,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(O)=O)C)=O)O,5462501.0,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,0.0029,,,10.1021/jm00122a003,Active,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,LZFZMUMEGBBDTC-QEJZJMRPSA-N
SD_209,HRWCVUIFMSZDJS-SZMVWBNQSA-N,19a,"(S)-7-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid",O=C(N1[C@H](C(O)=O)CC2(SCCS2)C1)[C@H](C)N[C@H](C(OCC)=O)CCC3=CC=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rat,0.092,,,10.1021/jm00127a033,Active,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2,HRWCVUIFMSZDJS-SZMVWBNQSA-N
SD_210,HRWCVUIFMSZDJS-SZMVWBNQSA-N,spirapril,"(S)-7-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid",CCOC([C@@H](N[C@H](C(N1CC2(SCCS2)C[C@H]1C(O)=O)=O)C)CCC3=CC=CC=C3)=O,5311447.0,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rat,0.67,,,10.1021/jm00127a033,Active,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2,HRWCVUIFMSZDJS-SZMVWBNQSA-N
SD_215,GBXSMTUPTTWBMN-XIRDDKMYSA-N,enalapril,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)C)=O)O,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)C)=O)O,5388962.0,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rat,1.273,,,10.1021/jm00127a033,Active,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,GBXSMTUPTTWBMN-XIRDDKMYSA-N
SD_217,RLAWWYSOJDYHDC-BZSNNMDCSA-N,lisinopril,((S)-1-carboxy-3-phenylpropyl)-L-lysyl-L-proline,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(O)=O)CCCCN)=O)O,5362119.0,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rat,0.00012,,,10.1021/jm00127a033,Active,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,RLAWWYSOJDYHDC-BZSNNMDCSA-N
SD_218,FAKRSMQSSFJEIM-RQJHMYQMSA-N,captopril,((S)-3-mercapto-2-methylpropanoyl)-L-proline,C[C@@H](C(N1CCC[C@H]1C(O)=O)=O)CS,44093.0,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rat,0.00129,,,10.1021/jm00127a033,Active,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,FAKRSMQSSFJEIM-RQJHMYQMSA-N
SD_239,GBXSMTUPTTWBMN-XIRDDKMYSA-N,enalapril,((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl-L-proline,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)C)=O)O,5388962.0,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.14,,,10.1021/jm00147a030,Active,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,GBXSMTUPTTWBMN-XIRDDKMYSA-N
SD_240,AWWFNGKCTHHBSZ-WPKBUWHJSA-N,MK-4229 ,((S)-1-carboxy-3-phenylpropyl)-L-alanyl-L-proline,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(O)=O)C)=O)O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.0031,,,10.1021/jm00147a030,Active,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,LZFZMUMEGBBDTC-QEJZJMRPSA-N
SD_241,FAKRSMQSSFJEIM-RQJHMYQMSA-N,captopril,((S)-3-mercapto-2-methylpropanoyl)-L-proline,C[C@@H](C(N1CCC[C@H]1C(O)=O)=O)CS,44093.0,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.013,,,10.1021/jm00147a030,Active,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,FAKRSMQSSFJEIM-RQJHMYQMSA-N
SD_278,ALRGMGVUAWHELZ-UHFFFAOYSA-N,23a(R+S),N-cyclopentyl-N-(3-mercapto-2-methylpropanoyl)glycine,O=C(O)CN(C1CCCC1)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.018,,,10.1021/jm00379a013,Active,CC(CS)C(=O)N(CC(=O)O)C1CCCC1,ALRGMGVUAWHELZ-UHFFFAOYSA-N
SD_279,ALRGMGVUAWHELZ-UHFFFAOYSA-N,23b,N-cyclopentyl-N-(3-mercapto-2-methylpropanoyl)glycine,O=C(O)CN(C1CCCC1)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.016,,,10.1021/jm00379a013,Active,CC(CS)C(=O)N(CC(=O)O)C1CCCC1,ALRGMGVUAWHELZ-UHFFFAOYSA-N
SD_333,FAKRSMQSSFJEIM-RQJHMYQMSA-N,2,((S)-3-mercapto-2-methylpropanoyl)-L-proline,C[C@@H](C(N1CCC[C@H]1C(O)=O)=O)CS,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.017,,,10.1021/jm00379a013,,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,FAKRSMQSSFJEIM-RQJHMYQMSA-N
SD_334,GBXSMTUPTTWBMN-XIRDDKMYSA-N,3,((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl-L-proline,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)C)=O)O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,8,,,10.1021/jm00379a013,,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,GBXSMTUPTTWBMN-XIRDDKMYSA-N
SD_338,LGLZPVSJGCVURZ-UHFFFAOYSA-N,7a,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-pentyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",O=C1N(CCCCC)N(CC2=CC=C(C3=CC=CC=C3C4=NNN=N4)C=C2)C5=NC=CC=C51,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.108,,,10.1021/jm7011563,,CCCCCn1c(=O)c2cccnc2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,LGLZPVSJGCVURZ-UHFFFAOYSA-N
SD_342,LGLZPVSJGCVURZ-UHFFFAOYSA-N,7e,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-pentyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",O=C1N(CCCCC)N(CC2=CC=C(C3=CC=CC=C3C4=NNN=N4)C=C2)C5=NC=CC=C51,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.053,,,10.1021/jm7011563,,CCCCCn1c(=O)c2cccnc2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,LGLZPVSJGCVURZ-UHFFFAOYSA-N
SD_367,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,Losartan,"(1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol",OCC1=C(N=C(N1CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2)CCCC)Cl,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.0067,,,10.1021/jm7011563,,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,PSIFNNKUMBGKDQ-UHFFFAOYSA-N
SD_368,ACWBQPMHZXGDFX-QFIPXVFZSA-N,Valsartan,"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine",CC([C@H](N(CC1=CC=C(C2=C(C3=NN=NN3)C=CC=C2)C=C1)C(CCCC)=O)C(O)=O)C,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.0034,,,10.1021/jm7011563,,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,ACWBQPMHZXGDFX-QFIPXVFZSA-N
SD_369,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,losartan,"(1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol",OCC1=C(N=C(N1CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2)CCCC)Cl,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.024,,,10.1016/S0960-894X(01)81117-3,,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,PSIFNNKUMBGKDQ-UHFFFAOYSA-N
SD_373,QFCDZSRVDUYPKU-HNNXBMFYSA-N,4c,"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-alanine",O=C(O)[C@@H](N(CC1=CC=C(C2=CC=CC=C2C3=NN=NN3)C=C1)C(CCCC)=O)C,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.011,,,10.1016/S0960-894X(01)81117-3,,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@@H](C)C(=O)O,QFCDZSRVDUYPKU-HNNXBMFYSA-N
SD_374,QFCDZSRVDUYPKU-HNNXBMFYSA-N,4d(R),"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-alanine",O=C(O)[C@@H](N(CC1=CC=C(C2=CC=CC=C2C3=NN=NN3)C=C1)C(CCCC)=O)C,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.104,,,10.1016/S0960-894X(01)81117-3,,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@@H](C)C(=O)O,QFCDZSRVDUYPKU-HNNXBMFYSA-N
SD_375,ACWBQPMHZXGDFX-QFIPXVFZSA-N,4e,"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine",O=C(O)[C@@H](N(CC1=CC=C(C2=CC=CC=C2C3=NN=NN3)C=C1)C(CCCC)=O)C(C)C,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.0014,,,10.1016/S0960-894X(01)81117-3,,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,ACWBQPMHZXGDFX-QFIPXVFZSA-N
SD_376,ACWBQPMHZXGDFX-QFIPXVFZSA-N,valsataran,"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine",CC([C@H](N(CC1=CC=C(C2=C(C3=NN=NN3)C=CC=C2)C=C1)C(CCCC)=O)C(O)=O)C,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,,,,10.1016/S0960-894X(01)81117-3,,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,ACWBQPMHZXGDFX-QFIPXVFZSA-N
SD_377,ACWBQPMHZXGDFX-QFIPXVFZSA-N,4f(R),"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine",O=C(O)[C@@H](N(CC1=CC=C(C2=CC=CC=C2C3=NN=NN3)C=C1)C(CCCC)=O)C(C)C,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.1,,,10.1016/S0960-894X(01)81117-3,,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,ACWBQPMHZXGDFX-QFIPXVFZSA-N
SD_431,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,losartan ,"(1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol",OCC1=C(N=C(N1CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2)CCCC)Cl,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0162,,,10.1016/j.ejmech.2012.01.009,,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,PSIFNNKUMBGKDQ-UHFFFAOYSA-N
SD_432,RMMXLENWKUUMAY-UHFFFAOYSA-N,Telmisartan,"4'-((1,7'-dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",CC1=CC(C2=NC3=CC=CC=C3N2C)=CC4=C1N=C(CCC)N4CC5=CC=C(C6=CC=CC=C6C(O)=O)C=C5,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.001,,,10.1016/j.ejmech.2012.01.009,,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,RMMXLENWKUUMAY-UHFFFAOYSA-N
SD_433,RMMXLENWKUUMAY-UHFFFAOYSA-N,Telmisartan,"4'-((1,7'-dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",CC1=CC(C2=NC3=CC=CC=C3N2C)=CC4=C1N=C(CCC)N4CC5=CC=C(C6=CC=CC=C6C(O)=O)C=C5,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.00049,,,h10.1021/jm200409s,,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,RMMXLENWKUUMAY-UHFFFAOYSA-N
SD_434,PACFDFGGIPMOKL-QFIPXVFZSA-N,2a,"(S)-3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine",CCC1=NC2=C(C)C=C(C)N=C2N1[C@H]3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0076,,,h10.1021/jm200409s,,CCc1nc2c(C)cc(C)nc2n1[C@H]1CCc2cc(-c3ccccc3-c3nnn[nH]3)ccc21,PACFDFGGIPMOKL-QFIPXVFZSA-N
SD_435,"3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-cyclopropyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine",2b(R+S),"(S)-3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine",CCC1=NC2=C(C)C=C(C)N=C2N1[C@H]3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.096,,,h10.1021/jm200409s,,CCc1nc2c(C)cc(C)nc2n1[C@H]1CCc2cc(-c3ccccc3-c3nnn[nH]3)ccc21,PACFDFGGIPMOKL-QFIPXVFZSA-N
SD_464,YDMPQPKAXQRBIE-UHFFFAOYSA-N,11e,4'-[[6-(4-Methylbenzoyl)amino-4-methyl-2-n-propyl-1Hbenzimidazol-1-yl]methyl]biphenyl-2-carboxylic acid,O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(NC(C5=CC=C(C)C=C5)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,0.0001,,,10.1016/j.ejmech.2013.08.014,,CCCc1nc2c(C)cc(NC(=O)c3ccc(C)cc3)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,YDMPQPKAXQRBIE-UHFFFAOYSA-N
SD_465,YDMPQPKAXQRBIE-UHFFFAOYSA-N,11f,4'-[[6-(4-Methylbenzoyl)amino-4-methyl-2-n-propyl-1Hbenzimidazol-1-yl]methyl]biphenyl-2-carboxylic acid,O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(NC(C5=CC=C(C)C=C5)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,0.0007,,,10.1016/j.ejmech.2013.08.014,,CCCc1nc2c(C)cc(NC(=O)c3ccc(C)cc3)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,YDMPQPKAXQRBIE-UHFFFAOYSA-N
SD_467,LSNPOGOZVAHETR-UHFFFAOYSA-N,13,2-methoxy-4-(5-nitro-1H-benzo[d]imidazol-2-yl)phenol,OC1=CC=C(C2=NC3=CC([N+]([O-])=O)=CC=C3N2)C=C1OC,,,,Ex vivo vascular reactivity functional assay.,,,,spontaneous hypertensive rats,,1.81 ± 0.08,,10.1016/j.bmc.2010.04.027,,COc1cc(-c2nc3cc([N+](=O)[O-])ccc3[nH]2)ccc1O,LSNPOGOZVAHETR-UHFFFAOYSA-N
